177 related articles for article (PubMed ID: 22812548)
1. The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia.
Chue P; Chue J
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):259-69. PubMed ID: 22812548
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacoeconomic review of the use of injectable long-acting risperidone].
Bartkó G; Fehér L
Neuropsychopharmacol Hung; 2005 Dec; 7(4):199-207. PubMed ID: 16496485
[TBL] [Abstract][Full Text] [Related]
3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
4. A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror-image study with national claim-based database in Taiwan.
Chang HC; Tang CH; Huang ST; McCrone P; Su KP
J Psychiatr Res; 2012 Jun; 46(6):751-6. PubMed ID: 22440883
[TBL] [Abstract][Full Text] [Related]
5. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.
Peuskens J; Olivares JM; Pecenak J; Tuma I; Bij de Weg H; Eriksson L; Resseler S; Akhras K; Jacobs A
Curr Med Res Opin; 2010 Mar; 26(3):501-9. PubMed ID: 20014981
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of long-acting risperidone in Sweden.
Hensen M; Heeg B; Löthgren M; van Hout B
Appl Health Econ Health Policy; 2010; 8(5):327-41. PubMed ID: 20804225
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
[TBL] [Abstract][Full Text] [Related]
8. Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison.
Dilla T; Möller J; O'Donohoe P; Álvarez M; Sacristán JA; Happich M; Tockhorn A
BMC Psychiatry; 2014 Dec; 14():298. PubMed ID: 25438678
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
10. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.
Keith S
Expert Rev Neurother; 2009 Jan; 9(1):9-31. PubMed ID: 19102665
[TBL] [Abstract][Full Text] [Related]
11. The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series.
Se Hyun Kim ; Dong Chung Jung ; Yong Min Ahn ; Yong Sik Kim
J Psychopharmacol; 2010 Jul; 24(7):981-6. PubMed ID: 19942641
[TBL] [Abstract][Full Text] [Related]
12. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
Barnett PG; Scott JY; Krystal JH; Rosenheck RA;
J Clin Psychiatry; 2012 May; 73(5):696-702. PubMed ID: 22697193
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.
Carswell C; Wheeler A; Vanderpyl J; Robinson E
Clin Drug Investig; 2010; 30(11):777-87. PubMed ID: 20712387
[TBL] [Abstract][Full Text] [Related]
14. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care.
Niaz OS; Haddad PM
Acta Psychiatr Scand; 2007 Jul; 116(1):36-46. PubMed ID: 17559599
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
[TBL] [Abstract][Full Text] [Related]
16. Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: an approach using generalised estimating equations.
Wu DB; Lee EH; Chung WS; Chow DP; Lee VW; Wong MC; Lee KK
Psychiatry Res; 2013 Dec; 210(3):745-50. PubMed ID: 24012164
[TBL] [Abstract][Full Text] [Related]
17. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.
Rosenheck RA; Krystal JH; Lew R; Barnett PG; Thwin SS; Fiore L; Valley D; Huang GD; Neal C; Vertrees JE; Liang MH;
Clin Trials; 2011 Apr; 8(2):196-204. PubMed ID: 21270143
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.
Ren XS; Crivera C; Sikirica M; Dirani R; Qian S; Kazis LE
J Clin Pharm Ther; 2011 Jun; 36(3):383-9. PubMed ID: 21062329
[TBL] [Abstract][Full Text] [Related]
20. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.
Achilla E; McCrone P
Appl Health Econ Health Policy; 2013 Apr; 11(2):95-106. PubMed ID: 23494934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
